354 related articles for article (PubMed ID: 934359)
1. Preferential deamination of dopamine by an A type monoamine oxidase in rat brain.
Waldmeier PC; Delini-Stula A; Maître L
Naunyn Schmiedebergs Arch Pharmacol; 1976; 292(1):9-14. PubMed ID: 934359
[TBL] [Abstract][Full Text] [Related]
2. Brain dialysis: in vivo metabolism of dopamine and serotonin by monoamine oxidase A but not B in the striatum of unrestrained rats.
Kato T; Dong B; Ishii K; Kinemuchi H
J Neurochem; 1986 Apr; 46(4):1277-82. PubMed ID: 2419508
[TBL] [Abstract][Full Text] [Related]
3. Monoamine oxidase-dependent metabolism of dopamine in the striatum and substantia nigra of L-DOPA-treated monkeys.
Di Monte DA; DeLanney LE; Irwin I; Royland JE; Chan P; Jakowec MW; Langston JW
Brain Res; 1996 Oct; 738(1):53-9. PubMed ID: 8949927
[TBL] [Abstract][Full Text] [Related]
4. Proceedings: Lack of significance of MAO-B for in vivo deamination of dopamine.
Waldmeier PC; Maître L
Naunyn Schmiedebergs Arch Pharmacol; 1975; 287 Suppl():R2. PubMed ID: 1143400
[No Abstract] [Full Text] [Related]
5. In vivo comparison of the effects of inhibition of MAO-A versus MAO-B on striatal L-DOPA and dopamine metabolism.
Brannan T; Prikhojan A; Martínez-Tica J; Yahr MD
J Neural Transm Park Dis Dement Sect; 1995; 10(2-3):79-89. PubMed ID: 9620056
[TBL] [Abstract][Full Text] [Related]
6. Deamination of norepinephrine, dopamine, and serotonin by type A monoamine oxidase in discrete regions of the rat brain and inhibition by RS-8359.
Kumagae Y; Matsui Y; Iwata N
Jpn J Pharmacol; 1991 Jan; 55(1):121-8. PubMed ID: 1904113
[TBL] [Abstract][Full Text] [Related]
7. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
Lamensdorf I; Youdim MB; Finberg JP
J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937
[TBL] [Abstract][Full Text] [Related]
8. L-3,4-dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors.
Wachtel SR; Abercrombie ED
J Neurochem; 1994 Jul; 63(1):108-17. PubMed ID: 8207420
[TBL] [Abstract][Full Text] [Related]
9. A and B forms of monoamine oxidase within the monoaminergic neurons of the rat brain.
Fagervall I; Ross SB
J Neurochem; 1986 Aug; 47(2):569-76. PubMed ID: 3734795
[TBL] [Abstract][Full Text] [Related]
10. Guinea pig striatum as a model of human dopamine deamination: the role of monoamine oxidase isozyme ratio, localization, and affinity for substrate in synaptic dopamine metabolism.
Azzaro AJ; King J; Kotzuk J; Schoepp DD; Frost J; Schochet S
J Neurochem; 1985 Sep; 45(3):949-56. PubMed ID: 3928811
[TBL] [Abstract][Full Text] [Related]
11. Selective monoamine oxidase subtype inhibition and striatal extracellular dopamine in the guinea-pig.
Ilani T; Lamensdorf I; Finberg JP
Br J Pharmacol; 2000 Aug; 130(8):1992-8. PubMed ID: 10952692
[TBL] [Abstract][Full Text] [Related]
12. Specificity of endogenous substrates for types A and B monoamine oxidase in rat striatum.
Schoepp DD; Azzaro AJ
J Neurochem; 1981 Jun; 36(6):2025-31. PubMed ID: 6787175
[TBL] [Abstract][Full Text] [Related]
13. Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats.
Finberg JP; Wang J; Goldstein DS; Kopin IJ; Bankiewicz KS
J Neurochem; 1995 Sep; 65(3):1213-20. PubMed ID: 7643100
[TBL] [Abstract][Full Text] [Related]
14. Comparison of short and long-lasting effects of pargyline on cerebral dopamine metabolism.
Waldmeier PC; Maître L
Naunyn Schmiedebergs Arch Pharmacol; 1976 Aug; 294(2):133-40. PubMed ID: 1012333
[TBL] [Abstract][Full Text] [Related]
15. Role of type A and B monoamine oxidase on the formation of 3,4-dihydroxyphenylacetic acid (DOPAC) in tissues from the brain of the rat.
Garrett MC; Soares-da-Silva P
Neuropharmacology; 1990 Oct; 29(10):875-9. PubMed ID: 2123970
[TBL] [Abstract][Full Text] [Related]
16. SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.
Aubin N; Barneoud P; Carter C; Caille D; Sontag N; Marc C; Lolivier J; Gardes A; Perron C; Le Kim A; Charieras T; Pandini M; Burnier P; Puech F; Jegham S; George P; Scatton B; Curet O
J Pharmacol Exp Ther; 2004 Sep; 310(3):1171-82. PubMed ID: 15178694
[TBL] [Abstract][Full Text] [Related]
17. Reversibility of the interaction of CGP 11305 A with MAO A in vivo.
Waldmeier PC; Feldtrauer JJ; Stoecklin K; Paul E
Eur J Pharmacol; 1983 Oct; 94(1-2):101-8. PubMed ID: 6197309
[TBL] [Abstract][Full Text] [Related]
18. The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions.
O'Carroll AM; Fowler CJ; Phillips JP; Tobbia I; Tipton KF
Naunyn Schmiedebergs Arch Pharmacol; 1983 Apr; 322(3):198-202. PubMed ID: 6408492
[TBL] [Abstract][Full Text] [Related]
19. Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration.
Green AR; Youdim MB
Br J Pharmacol; 1975 Nov; 55(3):415-22. PubMed ID: 1203627
[TBL] [Abstract][Full Text] [Related]
20. Increased L-DOPA-derived dopamine following selective MAO-A or -B inhibition in rat striatum depleted of dopaminergic and serotonergic innervation.
Sader-Mazbar O; Loboda Y; Rabey MJ; Finberg JP
Br J Pharmacol; 2013 Nov; 170(5):999-1013. PubMed ID: 23992249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
